ICH Q7 Training: GMP for Active Pharmaceutical Ingredients

Opens with an August 2026 FDA warning letter to Tianjin Kilo, an API manufacturer in China, issued after FDA reviewed its records instead of inspecting, finding no process validation, incomplete batch records, unvalidated test methods and no ongoing stability programme, followed by an import alert. The second case is Chemspec Chemicals in India, where batch records were missing and lots left without quality unit release, and the third is the 2020 testing of extended-release metformin for an impurity. Introduces ICH Q7, published by FDA as guidance and used by the EU as Part II of its GMP guide, and JKL Fine Chemicals in Mumbai, which makes metformin hydrochloride. Clears up myths about testing and validation, then explains the fourteen modules, four practice exercises and final exam, and ends with a recap.

What you will be able to do

• Explain why testing alone cannot show an API batch is good
• Describe how ICH Q7 is applied by FDA and in the EU
• Name the failures behind the three FDA cases

Why it matters

Seeing how missing validation and records cut off a supplier shows why controlling the process, not only the result, protects your supply.

Practice: Practice: Welcome: why API GMP matters · 3 questions

Starts at the gate of JKL Fine Chemicals in Mumbai, where two drums of chemicals arrive from suppliers that are not pharmaceutical plants, and asks whether those suppliers must follow GMP. Explains what an API is and how GMP for an API begins where the API starting material enters the process, a point the company designates, justifies and files. Shows how the stringency of GMP increases from the early steps to purification and packing, with the map JKL keeps of where GMP applies step by step, and what the guide excludes, with a contrasting example in Dublin. Then covers how FDA applies the guide as guidance backed by law, registration and its inspection programme, and how the EU applies it as Part II with audits and written confirmations. Ends with a recap.

What you will be able to do

• Identify the API starting material and where GMP begins
• Explain how GMP stringency increases through the process
• Describe how FDA and the EU each apply ICH Q7

Why it matters

Knowing exactly where GMP starts tells you which suppliers and steps need full controls, and which do not.

Practice: Practice: Where API GMP applies · 3 questions

Opens on a Friday evening at JKL Fine Chemicals, where a customer's truck waits for a metformin batch whose record is half reviewed and whose deviation is still open, and the production manager asks to ship now and finish the paperwork on Monday. Explains the principles of quality management and the duties of an independent quality unit: releasing every API, approving key documents, and making sure investigations, audits and reviews happen. Covers production's ownership of its instructions, records and deviations under written responsibilities, and how to judge a deviation such as a late cleaning log entry. Then shows internal audits and a summary of JKL's product quality review for metformin hydrochloride covering 2025, turning trends into decisions. Ends with why the quality unit needs time, people and authority, and a recap.

What you will be able to do

• Explain why only the quality unit can release an API batch
• Separate the responsibilities of the quality unit and production
• Use internal audits and the product quality review to find trends

Why it matters

A quality unit with time, people and authority stops a batch leaving early under pressure from a waiting truck.

Practice: Practice: The quality unit and the quality system · 3 questions

Starts in the drying room at JKL Fine Chemicals, where an operator with an open cut is about to unload dry metformin and an untrained new colleague offers to take over. Explains the requirements for people: enough of them, qualified, trained and assessed, and kept away from exposed API when ill or wounded, with a training record for a dryer operator and the use of consultants. Covers buildings designed to minimise contamination with defined areas and flows that prevent mix-ups, utilities that are qualified and monitored, and water shown to be suitable for its use. Then covers containment, with dedicated areas for penicillins and cephalosporins and a risk-based decision for potent or toxic APIs, decided in practice at a contract API manufacturer in Singapore. Ends with sanitation and a recap.

What you will be able to do

• Apply ICH Q7 rules on training, hygiene and illness for API staff
• Check that utilities and water are qualified and shown to be suitable
• Explain when dedicated or contained areas are required

Why it matters

Suitable means shown to be suitable; trained people and qualified utilities keep contamination out of an exposed API.

Practice: Practice: People, buildings and utilities · 3 questions

Opens in the milling room at JKL Fine Chemicals, where a shared mill carries a green clean tag after a campaign of another API, but the supervisor cannot find last night's cleaning record. Explains equipment fit for its use: the right design, non-reactive surfaces, use within its qualified range and identification. Covers cleaning with detailed procedures, defined residue limits, dirty and clean hold times, and a check before every use, shown in a page from the shared mill's log, where maintenance is recorded in the same history. Then covers calibration of instruments and validated computerised systems that record every change, with a micronising plant in Frankfurt as a second example. Ends with good practice, the common mistake and a recap.

What you will be able to do

• Check that equipment has a cleaning record behind its clean status
• Set cleaning procedures, residue limits and hold times
• Explain the controls ICH Q7 expects for computerised systems

Why it matters

A clean label needs a clean record behind it; without one, any residue of another API can reach the next batch.

Practice: Practice: Equipment, cleaning and computer systems · 3 questions

Starts with a night shift at an API plant where hourly dryer temperatures are filled in at the end of the shift from memory, the same pattern FDA saw in the case from Module 1. Explains a controlled document system in paper or electronic form, with entries made at the time, visible corrections and records kept for the right period, contrasting paper controls with system controls such as audit trails at a site in Tokyo. Covers master production instructions checked by the quality unit, batch records issued under control with a log of issued records, and complete laboratory records. Then shows JKL Fine Chemicals' checklist for reviewing batch MF-25-118 before release, including a late equipment log entry evaluated and closed. Ends with the common mistake, a recap and a practice exercise reviewing a batch record.

What you will be able to do

• Apply good documentation practice to API batch records
• Review a batch production record before release
• Explain why a late entry is a deviation, not a correction

Why it matters

A complete, contemporaneous batch record is the only way to show how an API batch was made when a customer or regulator asks.

Practice: Practice: Documentation and batch records · 3 questions

Opens at the tank farm of JKL Fine Chemicals, where a non-dedicated road tanker arrives with methanol for crystallisation and is about to discharge into a silo of tested, approved solvent. Explains how materials come from suppliers the quality unit has approved, with the real manufacturer known, and how every delivery is checked, coded and held in quarantine, with extra care for tankers and silos. Covers sampling and an identity test on every batch, and relying on suppliers' certificates of analysis only when full analyses show they can be trusted, using a solvent bought through a distributor in Hong Kong. Then covers storage and re-evaluation of materials. Ends with a recap and a practice exercise to plan receipt, sampling and reduced testing for a new starting material supplier.

What you will be able to do

• Approve suppliers with the real manufacturer known
• Plan receipt, quarantine, sampling and identity testing
• Decide when a supplier's certificate of analysis can be relied on

Why it matters

Identity testing and trusted certificates stop a contaminated delivery from spreading into a silo of approved material.

Practice: Practice: Materials management · 3 questions

Starts in the reaction hall at JKL Fine Chemicals, where an operator wants to start cooling the metformin reaction before the in-process test for remaining starting material has come back. Explains production operations: accurate, witnessed weighing, actual yields compared with expected yields and investigated, and time limits met where they apply, such as wet cake held in closed, labelled bins within a limit supported by hold studies. Covers in-process controls approved by the quality unit, tighter towards the end of the process, with every result recorded, and when qualified production staff can adjust within approved limits. Then covers blending only batches that each meet their specification, traceability and validation where physical attributes matter, and contamination control in steps such as crystallisation. Ends with a recap.

What you will be able to do

• Apply in-process controls and wait for results before the next step
• Investigate yields that differ from those expected
• Explain the rules for blending API batches

Why it matters

Blend good batches and never hide a bad one; in-process controls catch problems while they can still be fixed.

Practice: Practice: Production and in-process controls · 3 questions

Opens at the end of a packing run at JKL Fine Chemicals, where forty labels were printed for forty drums of metformin hydrochloride but the count shows forty-two were used or went missing. Explains packaging that protects the API, made of clean, non-reactive materials checked against specifications, with labels and drum liners treated as controlled materials. Covers label control: locked storage, checks, reconciliation and complete information for the next user, shown on the label for batch MF-25-118. Then covers warehousing and distribution that keep the labelled conditions, with drums shipped by sea to tablet makers in Boston and Frankfurt with data loggers, moves in quarantine, and a shipment through a logistics hub in Dubai. Ends with tracing any batch to all its customers in minutes, and a recap.

What you will be able to do

• Reconcile labels so every one is used, returned or destroyed
• Check API labels carry the information the next user needs
• Trace any API batch to all its customers

Why it matters

A missing label with a batch number can end up on the wrong drum; reconciliation and traceability prevent mix-ups and speed recalls.

Practice: Practice: Packaging, labels, storage, distribution · 3 questions

Starts with the metformin case from Module 1, where a private laboratory and FDA tested the same samples for NDMA with different methods and reached different results, a lesson that a result is only as good as the method behind it. Explains scientifically sound methods, validated or verified, and investigating every out-of-specification result by procedure. Covers controlled reference standards, an impurity profile that tracks the process, and complete, authentic certificates of analysis, showing what JKL Fine Chemicals puts on its certificate and an API repacker in London that issues its own. Then covers an ongoing stability programme that supports the retest date, and reserve samples kept in the right quantity and packaging, with a reserve sample log. Ends with a recap.

What you will be able to do

• Investigate an out-of-specification result by procedure
• Explain what a complete, authentic certificate of analysis contains
• Set a retest date supported by an ongoing stability programme

Why it matters

Sound methods and honest certificates are what customers rely on; a weak method can hide an impurity or raise a false alarm.

Practice: Practice: Laboratory controls and stability · 3 questions

Opens with a shift team at JKL Fine Chemicals that starts drying at a higher temperature to save three hours per batch, without realising the drying temperature is a critical parameter. Explains validation starting from a written policy and qualified equipment, from design to performance qualification, with prospective process validation as the normal choice. Covers keeping the validated state through periodic review, cleaning validation and monitoring. Then covers change control: every change assessed and approved by the quality unit, shown in the change record JKL raised once QA found out, and advance notification to JKL Pharma and customers in the US and the EU whose API could be affected. Ends with following one change from request to closure in the change log, a recap and a practice exercise assessing a change of starting material supplier.

What you will be able to do

• Explain why prospective process validation is the normal choice
• Keep the validated state through periodic review and monitoring
• Assess a change and decide when customers must be notified

Why it matters

No change without assessment and no surprise for customers keeps validated processes valid and supply contracts intact.

Practice: Practice: Validation and change control · 3 questions

Starts with a difficult week at JKL Fine Chemicals, when two metformin batches fail: one is too coarse after milling and one has an impurity above its limit, and both are quarantined at once. Explains how failed and returned materials are identified and quarantined until the quality unit decides. Covers the difference between reprocessing, which repeats an established step, and reworking, which uses a different one and needs an investigation and evidence of equivalent quality, plus recovery of materials and solvents. Then covers returns with a returns log, and complaints recorded, investigated and trended under a written procedure, shown in a complaint record from a customer in Boston, and a written recall procedure. Ends with a recap and a practice exercise deciding what to do with the two failed batches.

What you will be able to do

• Tell reprocessing apart from reworking for a failed API batch
• Decide what evidence a reworked batch needs before release
• Record, investigate and trend complaints, and plan a recall

Why it matters

A rescued batch is still a signal; handling it by the rules protects patients and shows inspectors the system works.

Practice: Practice: Rejection, re-use, complaints, recalls · 3 questions

Opens with an API trader that repacks bulk API into small tins under its own label and certificate, so the customer cannot tell who made the API or which batch it came from. Explains how contract manufacturers and laboratories follow the guide under written agreements, with the contract giver keeping overall responsibility. Covers agents, brokers, traders, distributors and repackers keeping the chain traceable to the original manufacturer and sharing information both ways, shown in JKL Fine Chemicals' quality agreement with its distributor in Dubai serving customers in the Gulf. Then covers the two special cases: APIs made by cell culture or fermentation, and APIs for use in clinical trials, which follow the extra guidance the guide gives for them. Ends with a recap.

What you will be able to do

• Write the key terms of a quality agreement with a contractor or distributor
• Check that a trader's certificate traces back to the original maker
• Explain the extra guidance for fermentation and clinical-trial APIs

Why it matters

The original maker is never a secret; traceable supply chains protect customers from APIs of unknown origin.

Practice: Practice: Contractors, agents and special APIs · 3 questions

Starts with a sentence from FDA's compliance programme for API inspections, issued in August 2025: the failure of a system puts all of a manufacturer's APIs at risk. Links this back to the cases in Module 1, then explains how FDA groups an API site into six systems, with the quality system always covered. Follows JKL Fine Chemicals' team as it traces one batch through every system, grading each as in control or not, finding issues such as a trader's certificate that does not name the original manufacturer and yields trending down, and naming an owner and a date for every fix. Ends with a five-step road map with a yearly review of all six systems, a recap, and the final exam.

What you will be able to do

• Explain FDA's six-system approach to API inspections
• Trace one batch through every system to judge control
• Build a five-step road map for your own site

Why it matters

Reviewing your site the way FDA does shows which systems are out of control before an inspector finds them.

Practice: Practice: Putting it together · 3 questions